Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis

Severe Alcoholic Hepatitis Clinical Trial

Official title: Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis.

Status Not yet recruiting

Clinical Trial Summary

Severity of alcoholic hepatitis is defined by Maddrey's discriminant function, value of 32 or higher indicates severe alcoholic hepatitis that carries an adverse prognosis with one month mortality of 30%-50%. Prednisolone (40 mg/day) given orally should be considered to improve 28-day mortality in patients with severe AH. Abstinence is key to long-term survival.

According to current protocol, we discontinue the treatment after 28 days but only 15 % patient is achieving the DF < 32 after 28 days of treatment.

The aim of this study is to evaluate the role of extended low dose prednisolone (10mg) in achieving remission by day-90 in steroid responsive severe alcoholic hepatitis.

Clinical Trial Description

Study Design- Single center, Open label, Randomized controlled trial

• According to current protocol, we discontinue the treatment after 28 days, it improve the mortality rate in severe alcoholic patient with mDF score of more than 32 but only 15% patient is achieving the mDF < 32 after 28 days of treatment.

• Abstinence is key to long-term survival. No data is available in giving steroids for more than 28days going to improve clinical or biochemical parameter of the patient.

Methodology:

• Study population: All patients aged ≥ 18 years and ≤ 60 years admitted in Institute of Liver and Biliary Sciences, New Delhi with Severe Alcoholic hepatitis mDF of more than 32 days after 28days of steroid therapy and are giving written consent for participation in the study. Option of LDLT, Plasma exchange, FMT, GM- CSF given to patient with DF more than 32 after 28 days of steroid therapy and these patients are excluded from the study.

• Study period - 1.5 years after IEC approval

• Sample size - We are enrolling 150 patients.- Assuming that the response rate is 50% in prednisolone + SMT group and 20% in only SMT group. With alpha- 5% and power of 80, we need to enroll - 90 cases i.e, 45 in each group. Further adding 10% drop out cases, it was decided to enroll 100 patients i.e, 50 in each group. Allocation will be done randomly by block randomization panel by block size of 10. Further assuming that DF > 32 will be in 80% cases we need to enroll 125 cases. Further 80% will have lille score < 0.45, so it is to decide to enroll 150 cases.

• Intervention - Extended steroid group: 10mg of prednisolone plus standard medical therapy for 60 days.

• Placebo group: Standard treatment plus placebo that the patient would receive included in the trial.

• SMT- IV Albumin, Diuretics, Multi vitamins as per clinicians decision

• Monitoring and assessment:

• Investigations - Tests performed on Day 0, 4, 7, 28, 60 and 90.

• Routine: CBC, RFT, LFT, PT/INR, CXR, PCT, Urine R/M & C/S, Blood C/S,

• Blood sugar- fasting & PP.

• Statistical Analysis: The data will be represented as mean ± SD. The categorical data will be analysed using Chi-square test. The continuous data will be analysed by student T test, or Mann-Whitney test, whichever is applicable. Besides this, Cox regression will be applied to analyse the variables. For all tests, p≤ 0.05 will be considered statistically significant

• Adverse effects

• New onset Diabetes, risk of infection

• Stopping rule

• Discontinuation of steroids (variceal bleed, infections, uncontrolled sugars, new onset AKI)

• Death

• Liver transplantation

• Lapse or relapse of alcohol consumption

Expected outcome of the project:

• Improvement in the mDF score (<32) i.e. Remission in severe alcoholic hepatitis. ;

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis, Alcoholic
• Severe Alcoholic Hepatitis

• NCT number: NCT06155760
• Study type: Interventional
• Source: Institute of Liver and Biliary Sciences, India
• Contact: Dr Ravi Nishad, MD
• Phone: 01146300000
• Email: ravinishad.422@gmail.com
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 25, 2023
• Completion date: February 27, 2025